CDH1 and cancer: miR-200 inhibition can reduce the level of E-cadherin whilst augmenting vimentin expression, which, in addition to affecting cell motility, can also lead to the acquisition of mesenchymal phenotypes, thus leading to the development of anti-cancer therapy resistance.34